What invalidating breast cancer gene patents implies
I don't think there was any expectation that it was going to be anything different and that there would be any significant negative impact as a result." patentable.
I certainly have no objection to scientific research ... 4,438,032 Predictably, Myriad Genetics recently appealed a federal district court's recent decision rendering seven of its lucrative BRCA1 and BRCA2 gene patents invalid.
The verdict invalidates the patents Myriad Genetics has held on breast cancer genes BRCA1 and BRCA2 since the 1990's and allows other labs besides theirs to test for mutations in those genes which, when present, strongly indicate a genetic predisposition to cancer.
It also means that scientists can move forward in their genetic research without threat of being sued for copyright infringement.
It’s a question that’s difficult to answer prospectively, but Andrew Pollack’s piece in succinctly makes an important point about an emerging reality in the biotechnology industry.Sweet of the United States District Court for the Southern District of New York issued a jaw-dropping summary judgment ruling (pdf) in that invalidates certain of Myriad Genetics’ patents related to the BRCA 1 and 2 breast and ovarian cancer susceptibility genes.In a post written immediately after the release of the opinion, Dan gave a thorough summary of the ruling.In terms of fairness and power, is it ethical to patent the human body?Introduction Imagine you are financially challenged and your mother and grandmother have breast cancer.
In order to use Medscape, your browser must be set to accept cookies delivered by the Medscape site.